912656-34-9

Usage

Uses

Used in Pharmaceutical Industry:
XEN907 is used as a therapeutic agent for the treatment of neurological and psychiatric disorders due to its high potency and selectivity for the Kv7.2/7.3 potassium channel. Its ability to reduce neuronal excitability and epileptic activity makes it a potential treatment for conditions such as epilepsy, neuropathic pain, and mood disorders.
Used in Neurological Disorders Treatment:
XEN907 is used as an anticonvulsant agent for the treatment of epilepsy, as it has been shown to reduce neuronal excitability and epileptic activity in preclinical studies.
Used in Pain Management:
XEN907 is used as an analgesic agent for the management of neuropathic pain, leveraging its ability to modulate neuronal excitability and reduce pain signals.
Used in Mood Disorders Treatment:
XEN907 is used as a mood stabilizer for the treatment of mood disorders, as its modulation of neuronal excitability may help in alleviating symptoms associated with these conditions.
Used in Drug Development:
XEN907 is used as a lead compound in the development of new pharmaceuticals targeting the Kv7.2/7.3 potassium channel, due to its favorable pharmacokinetic properties and potential therapeutic applications in various neurological and psychiatric disorders.

Upstream product

• 91-56-5 indole-2,3-dione 
• 4290-90-8 1-pentylisatin 
• 912669-99-9 3-hydroxy-3-(6-hydroxy-1,3-benzodioxol-5-yl)-1-pentyl-1,3-dihydro-2H-indol-2-one 
• 533-31-3 Sesamol 

Relevant academic research and scientific papers

Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain

Starting from the oxindole 2a identified through a high-throughput screening campaign, a series of NaV1.7 blockers were developed. Following the elimination of undesirable structural features, preliminary optimization of the oxindole C-3 and N-1 substituents afforded the simplified analogue 9b, which demonstrated a 10-fold increase in target potency versus the original HTS hit. A scaffold rigidification strategy then led to the discovery of XEN907, a novel spirooxindole NaV1.7 blocker. This lead compound, which in turn showed a further 10-fold increase in potency, represents a promising structure for further optimization efforts.

USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.

SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.